vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and LXP Industrial Trust (LXP). Click either name above to swap in a different company.
LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $83.5M, roughly 1.0× BillionToOne, Inc.). LXP Industrial Trust runs the higher net margin — 33.2% vs 6.8%, a 26.3% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -14.0%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
BLLN vs LXP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $86.7M |
| Net Profit | $5.7M | $28.8M |
| Gross Margin | 69.9% | 81.5% |
| Operating Margin | 11.5% | 34.6% |
| Net Margin | 6.8% | 33.2% |
| Revenue YoY | 117.4% | -14.0% |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $86.7M | ||
| Q3 25 | $83.5M | $86.9M | ||
| Q2 25 | — | $87.7M | ||
| Q1 25 | — | $88.9M | ||
| Q4 24 | — | $100.9M | ||
| Q3 24 | $38.4M | $85.6M | ||
| Q2 24 | — | $85.8M | ||
| Q1 24 | — | $86.3M |
| Q4 25 | — | $28.8M | ||
| Q3 25 | $5.7M | $36.3M | ||
| Q2 25 | — | $29.1M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.9M | $6.3M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | — | $-269.0K |
| Q4 25 | — | 81.5% | ||
| Q3 25 | 69.9% | 82.3% | ||
| Q2 25 | — | 81.9% | ||
| Q1 25 | — | 80.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | 52.6% | 82.5% | ||
| Q2 24 | — | 82.0% | ||
| Q1 24 | — | 82.4% |
| Q4 25 | — | 34.6% | ||
| Q3 25 | 11.5% | 50.4% | ||
| Q2 25 | — | 33.7% | ||
| Q1 25 | — | 21.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -32.9% | 7.9% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 33.2% | ||
| Q3 25 | 6.8% | 41.7% | ||
| Q2 25 | — | 33.2% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -38.8% | 7.4% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | -0.3% |
| Q4 25 | — | — | ||
| Q3 25 | $0.10 | $0.12 | ||
| Q2 25 | — | $0.09 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.47 | $0.02 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $170.4M |
| Total DebtLower is stronger | $55.0M | $1.4B |
| Stockholders' EquityBook value | $-239.5M | $2.0B |
| Total Assets | $327.5M | $3.5B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $170.4M | ||
| Q3 25 | $195.2M | $229.7M | ||
| Q2 25 | — | $71.0M | ||
| Q1 25 | — | $70.9M | ||
| Q4 24 | — | $101.8M | ||
| Q3 24 | — | $55.0M | ||
| Q2 24 | — | $48.7M | ||
| Q1 24 | — | $293.8M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | $55.0M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $-239.5M | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $-242.9M | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $3.5B | ||
| Q3 25 | $327.5M | $3.7B | ||
| Q2 25 | — | $3.7B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | — | $3.9B | ||
| Q1 24 | — | $4.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $188.7M |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | 6.56× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $188.7M | ||
| Q3 25 | $13.8M | $63.5M | ||
| Q2 25 | — | $44.3M | ||
| Q1 25 | — | $39.0M | ||
| Q4 24 | — | $211.2M | ||
| Q3 24 | — | $64.6M | ||
| Q2 24 | — | $38.5M | ||
| Q1 24 | — | $38.9M |
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 6.56× | ||
| Q3 25 | 2.42× | 1.75× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 2.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.18× | ||
| Q2 24 | — | 7.09× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
LXP
Segment breakdown not available.
